Latest Medical research Stories

ANN ARBOR, Mich., Oct. 4, 2012 /PRNewswire/ -- Molecular Imaging, Inc. has expanded its preclinical nuclear medicine program with the addition of Single Photon Emission Computed Tomography (SPECT) imaging. This decision was driven by the growing industry understanding of the value of in vivo molecular imaging throughout the entire drug development process. SPECT is an exciting preclinical modality that allows researchers to 'tag' potential treatments with a variety of radioactive...

ROTTERDAM, The Netherlands, October 4, 2012 /PRNewswire/ -- Viroclinics Biosciences B.V. has relocated to the Rotterdam Science Tower, a new high-tech science facility that's about to become a hotspot for international life sciences, medical innovations and spin-offs from Erasmus MC and Erasmus University Rotterdam. This location will form the core of a powerful cluster of biomedical businesses, bringing a vast range of medical knowledge and business activity together within a...

Kansas State University researchers have discovered a molecule that may be capable of delivering drugs inside the body to treat diseases. For the first time, researchers have designed and created a membrane-bounded vesicle formed entirely of peptides -- molecules made up of amino acids, the building blocks of protein. The membrane could serve as a new drug delivery system to safely treat cancer and neurodegenerative diseases. A study led by John Tomich, professor of biochemistry at...

PASADENA, Calif., Sept. 20, 2012 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE), the leading owner, operator, and developer of high-quality, sustainable real estate for the broad and diverse life science industry, is honored to announce that Roche Holding Ltd will establish its new Translational Clinical Research Center (TCRC) at the Alexandria Center for Life Science - New York City. The TCRC will be the mission-critical presence for Roche Pharma Research and...

SAN DIEGO, Sept. 19, 2012 /PRNewswire/ -- Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today announced that FierceBiotech named Celladon as one of 2012's Fierce 15, designating it as one of the most promising private biotechnology companies in the industry. This is FierceBiotech's tenth annual Fierce 15 selection. "You don't often find three Big Pharmas clustered together in a single...

COLUMBIA, Md., Sept. 19, 2012 /PRNewswire/ -- BioFortis Inc., a leading software company in the clinical and translational research space, today introduced its Next Generation Biobanking software platform for biomarker-based clinical research. It will help pharmaceutical, government and academic research centers involved in biomarker-based clinical and translational studies to safely and effectively conduct externalized, science-driven collaborative studies. As biomarker-based...

BASKING RIDGE, N.J., Sept. 12, 2012 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David J. Mazzo, PhD, President and CEO, will be presenting at the UBS Global Life Sciences Conference at 2:00 p.m. ET on September 19, 2012 at the Grand Hyatt in New York City. The presentation will include an overview of the Company's pipeline with emphasis on the lead development program,...

ZURICH, Switzerland, September 4, 2012 /PRNewswire/ -- Eirini Fragkiadaki, a young veterinarian and researcher at the Pasteur Institute in Athens, is dedicated to developing her university's Department for Animal Research according to the 3R rule (Replace, Reduce, Refine). In the coming years she will focus on education and training and promote the high-quality ethical and scientific standards of the Basel Declaration Society in all issues affecting animal experiments....

BEVERLY HILLS, Calif., Aug. 30, 2012 /PRNewswire/ -- The Million Women Study is a study, conducted by UK researchers, of women's health analyzing data from more than one million women aged 50 and over. It is a collaborative project between Cancer Research UK and the National Health Service (NHS), with additional funding from the Medical Research Council (UK). The study has abundantly fulfilled its aims of illuminating the answers to crucial questions about factors affecting the health...

BASKING RIDGE, N.J, Aug. 29, 2012 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David J. Mazzo, PhD, President and CEO, will be presenting at the Stifel Nicolaus Healthcare Conference 2012 at 3:15 p.m. ET on September 5, 2012 at the Four Seasons Hotel in Boston, MA. The presentation will include an overview of the Company's pipeline with emphasis on the lead development...